<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310050</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000466320</org_study_id>
    <secondary_id>CCCWFU-57103</secondary_id>
    <secondary_id>LILLY-H3E-US-X031</secondary_id>
    <secondary_id>CCCWFU-BG04-529</secondary_id>
    <nct_id>NCT00310050</nct_id>
  </id_info>
  <brief_title>Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>A Phase I Dose-Escalating Study of Induction Gemcitabine/Pemetrexed Followed by Pemetrexed and Concurrent Upper Abdominal Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes
      needed for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Radiation therapy uses high energy x-rays to kill tumor cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed when
      given together with radiation therapy in treating patients with locally advanced pancreatic
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum tolerated dose of pemetrexed disodium when given in combination
           with upper abdominal radiotherapy after induction therapy comprising gemcitabine
           hydrochloride and pemetrexed disodium followed by consolidation therapy with gemcitabine
           hydrochloride in patients with locally advanced pancreatic cancer.

        -  Determine the quantitative toxicity of this regimen in these patients.

      Secondary

        -  Determine the quantitative and qualitative dose-limiting toxicities of pemetrexed
           disodium in combination with upper abdominal radiation therapy.

        -  Evaluate patterns of failure, response, and survival of these patients at 1 year

      OUTLINE: This is an open-label, nonrandomized, dose-escalation study of pemetrexed disodium.

        -  Induction therapy: Patients receive pemetrexed disodium IV over 10 minutes and
           gemcitabine hydrochloride IV over 30 minutes on day 1. Treatment repeats every 14 days
           for 3 courses. Approximately 2 weeks later, patients without disease progression proceed
           to chemoradiotherapy.

        -  Chemoradiotherapy: Patients receive pemetrexed disodium IV over 10 minutes on days 1,
           15, and 29 and undergo radiotherapy once daily 5 days a week for 5 ½ weeks.
           Approximately 2-3 weeks later, patients without disease progression proceed to
           consolidation therapy.

      Cohorts of 3-9 patients receive escalating doses of pemetrexed disodium during
      chemoradiotherapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as
      the dose at which ≤ 20% or ≤ 2 of 9 patients experience dose-limiting toxicity.

        -  Consolidation therapy: Patients receive gemcitabine hydrochloride IV over 30 minutes on
           days 1 and 8. Treatment repeats every 21 days for 2 courses in the absence of disease
           progression or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically.

      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Maximum Tolerated Dose of Pemetrexed When Administered With Concomitant Radiation Therapy</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative Toxicity of Pemetrexed When Administered With Concomitant Radiation Therapy</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualitative Dose-limiting Toxicities of Pemetrexed in Combination With Radiation Therapy</measure>
    <time_frame>42 days</time_frame>
    <description>Toxicity will be determined using the revised NCI Common Toxicity Criteria (CTC) version 3.0 for Toxicity and Adverse Event Reporting. Number of events with grade 1-5 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of Failure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of Response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Survived</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Pemetrexed in combination with concomitant radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Pemetrexed plus Radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <description>500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).</description>
    <arm_group_label>Pemetrexed in combination with concomitant radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
    <arm_group_label>Pemetrexed in combination with concomitant radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed carcinoma arising from the pancreas

               -  Stage II or III disease, meeting 1 of the following criteria:

                    -  Nonresectable disease

                    -  Potentially resectable disease

                    -  Resectable disease

               -  Stage IV disease with symptomatic back pain requiring palliation allowed at the
                  discretion of the principal investigator

          -  Measurable, evaluable, or nonmeasurable disease

          -  No neuroendocrine tumor of the pancreas

          -  No documented brain metastasis

          -  No clinically significant pleural or peritoneal effusions that cannot be drained

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Life expectancy ≥ 12 weeks

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9 g/dL

          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 3 times ULN (5 times ULN if liver has tumor involvement)

          -  AST and ALT ≤ 3 times ULN (5 times ULN if liver has tumor involvement)

          -  Creatinine clearance ≥ 45 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  No active infection

          -  No serious systemic disorders that would preclude study treatment

          -  No significant cardiovascular disease in the form of abnormal electrocardiogram
             coupled with clinical features of recent or recurrent cardiac disease (including
             myocardial infarction, angina, or hypertension)

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior investigational agents

          -  No prior chemotherapy for pancreatic cancer

          -  Must be able to discontinue aspirin, dexamethasone, and other nonsteroidal
             anti-inflammatory agents for 2 days before, the day of, and 2 days after pemetrexed
             disodium dose (5 days before for long-acting agents such as piroxicam)

          -  Must be able and willing to take folic acid and cyanocobalamin (vitamin B12)
             supplementation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur William Blackstock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <results_first_submitted>November 1, 2018</results_first_submitted>
  <results_first_submitted_qc>November 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2018</results_first_posted>
  <last_update_submitted>November 28, 2018</last_update_submitted>
  <last_update_submitted_qc>November 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
          <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
          <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="2.645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Maximum Tolerated Dose of Pemetrexed When Administered With Concomitant Radiation Therapy</title>
        <time_frame>42 days</time_frame>
        <population>data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
            <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Maximum Tolerated Dose of Pemetrexed When Administered With Concomitant Radiation Therapy</title>
          <population>data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quantitative Toxicity of Pemetrexed When Administered With Concomitant Radiation Therapy</title>
        <time_frame>42 days</time_frame>
        <population>data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
            <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Toxicity of Pemetrexed When Administered With Concomitant Radiation Therapy</title>
          <population>data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Qualitative Dose-limiting Toxicities of Pemetrexed in Combination With Radiation Therapy</title>
        <description>Toxicity will be determined using the revised NCI Common Toxicity Criteria (CTC) version 3.0 for Toxicity and Adverse Event Reporting. Number of events with grade 1-5 will be reported.</description>
        <time_frame>42 days</time_frame>
        <population>Data available for 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
            <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
          </group>
        </group_list>
        <measure>
          <title>Qualitative Dose-limiting Toxicities of Pemetrexed in Combination With Radiation Therapy</title>
          <description>Toxicity will be determined using the revised NCI Common Toxicity Criteria (CTC) version 3.0 for Toxicity and Adverse Event Reporting. Number of events with grade 1-5 will be reported.</description>
          <population>Data available for 2 participants.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patterns of Failure</title>
        <time_frame>1 year</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
            <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Failure</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patterns of Response</title>
        <time_frame>1 year</time_frame>
        <population>Data not collected on all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
            <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Response</title>
          <population>Data not collected on all participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Survived</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
            <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Survived</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pemetrexed in Combination With Concomitant Radiotherapy</title>
          <description>Patients will receive Pemetrexed plus Radiotherapy.
pemetrexed disodium: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
Radiotherapy: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Calcium, serum-high</sub_title>
                <description>hypercalcemia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low</sub_title>
                <description>hypocalcemia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemoglobin (gender based)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC) (4.8-10.8)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <description>(160-360)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high</sub_title>
                <description>(hyperkalemia) (3.5-5.3)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Watery eye</sub_title>
                <description>(epiphora, tearing)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <description>serum glutamic pyruvic transaminase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Stomach</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>asthenia, lethargy, malaise</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <description>in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC) 1.6-7.3</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <description>Penis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, serum-high</sub_title>
                <description>hyperglycemia</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low</sub_title>
                <description>hypoglycemia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <description>sensory</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high</sub_title>
                <description>(hypernatremia) (135-146)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>limb</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>trunk/genital</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>dermatitis associated with radiation</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Blackstock</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>3367136501</phone>
      <email>ablackst@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

